Dr. Ying Yu, MD, PhD
Scientific Director of Oligonucleotides Therapeutics Platform and Ophthalmology Oligonucleotide, Oligo Conjugates, Target Discovery, Target Validation, Ion Channels, Pulmonary and Respiratory Disease, Sensory Disease
Dr. Ying Yu, MD, PhD, is the Scientific Director of the Oligonucleotide Platform at WuXi Biology and Testing, leading platform development and discovery initiatives. He brings more than 25 years of academic and pharmaceutical experience spanning molecular biology, physiology, ophthalmology, and RNAi-based therapeutics. Previously, Dr. Yu was Associate Director at AbbVie where he established an siRNA discovery platform for ocular diseases and led bioanalytical strategy for antibody-siRNA conjugates. He also held senior scientific roles at Allergan and Novartis/Alcon, including work demonstrating durable retinal target modulation following intravitreal siRNA administration. Dr. Yu earned his MD from Soochow University and PhD from Showa Medical University. He holds multiple patents and has authored more than 30 peer-reviewed publications.